You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

Seretide at all doses and devices is indicated in the regular treatment of asthma for patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist or patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist.

The Seretide 50/500mg Diskus is also licensed for regular use in COPD for patients with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy. For further indication details please refer to the SPC

Over 102.49 million patient treatment years and counting1

Three strengths in two different devices: metered dose inhaler (MDI) and dry powder inhaler (DPI)2

Studied in over 90 clinical trials3

Seretide resources

We have a number of Seretide resources available to order.


  1. Data on file: RF/SFC/0008/15(2) Dec 2016. This figure is taken from the Seretide DSUR 2016N296472 with Patient Exposure as of June 2016 and is an estimate based on IMS heath data.
  2. Seretide SPC, accessed January 2018.
  3. WHO clinical trials search portal, accessed March 2017.

Seretide, Diskus and Evohaler are a registered trademarks of the GlaxoSmithKline group of companies